#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	2752	16S	1529	1529	100.0	16S.l15.c4.ctg.1	2552	316.2	1	SNP	n	C1184T	0	.	.	1184	1184	C	1674	1674	C	394	C	327	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4554	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4094	333.1	0	.	n	.	0	T695C	SNP	695	695	T	1311	1311	C	326	C,A	272,3	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4554	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4094	333.1	0	.	n	.	0	G1337A	SNP	1337	1337	G	1953	1953	A	390	A	337	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4554	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4094	333.1	0	.	n	.	0	T1971C	SNP	1971	1971	T	2587	2587	C	429	C,A	367,3	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4554	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4094	333.1	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	3213	3213	T	414	T,G	350,2	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	4554	23S	2890	2890	99.86	23S.l15.c4.ctg.1	4094	333.1	1	SNP	n	A2045G	0	.	.	2045	2045	A	2661	2661	A	460	A	384	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
folP.WHO_P_01364c	folP.WHO_P_01364c	1	1	27	462	folP	852	852	100.0	folP.l15.c4.ctg.1	1897	73.0	1	SNP	p	R228S	1	.	.	682	684	AGC	1181	1183	AGC	109;110;110	A;G;C	88;95;93	folP.WHO_P_01364c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1014	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3924	77.5	1	SNP	p	S91F	0	.	.	271	273	TCC	865	867	TCC	97;98;98	T;C;C	88;85;88	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1014	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3924	77.5	1	SNP	p	D95G	0	.	.	283	285	GAC	877	879	GAC	96;97;98	G,C;A,C;C	81,1;83,1;86	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	1014	gyrA	2751	2751	99.85	gyrA.l15.c4.ctg.1	3924	77.5	1	SNP	p	D95N	0	.	.	283	285	GAC	877	879	GAC	96;97;98	G,C;A,C;C	81,1;83,1;86	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	354	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1736	61.0	0	.	p	.	0	A39T	NONSYN	115	117	GCC	625	627	ACC	109;109;108	A;C;C	93;95;91	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	354	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1736	61.0	0	.	p	.	0	R44H	NONSYN	130	132	CGC	640	642	CAC	111;111;111	C;A,C;C	95;98,1;96	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	354	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1736	61.0	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	823	825	CAC	107;108;108	C;A;C	95;96;96	.	.
mtrR.WHO_Y_01506	mtrR.WHO_Y_01506	1	1	539	354	mtrR	633	633	99.21	mtrR.l15.c4.ctg.1	1736	61.0	1	SNP	p	G45D	0	.	.	133	135	GGC	643	645	GGC	111;111;111	G;G;C	98;99;100	mtrR.WHO_Y_01506:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	292	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1452	60.1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	982	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3384	86.5	1	SNP	p	D86N	0	.	.	256	258	GAC	834	836	GAC	101;100;99	G;A;C	82;81;81	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	982	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3384	86.5	1	SNP	p	S87I	0	.	.	259	261	AGT	837	839	AGT	99;100;100	A;G;T	82;85;81	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	982	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3384	86.5	1	SNP	p	S87W	0	.	.	259	261	AGT	837	839	AGT	99;100;100	A;G;T	82;85;81	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	982	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3384	86.5	1	SNP	p	S87R	0	.	.	259	261	AGT	837	839	AGT	99;100;100	A;G;T	82;85;81	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	982	parC	2304	2304	100.0	parC.l6.c4.ctg.1	3384	86.5	1	SNP	p	S88P	0	.	.	262	264	TCC	840	842	TCC	101;101;101	T,G;C;C	84,1;85;87	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	834	parE	1986	1986	100.0	parE.l6.c4.ctg.1	3056	81.4	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1758	1760	GGC	110;109;109	G,A;G,A;C,G	88,1;92,1;93,1	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	752	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2786	80.7	1	SNP	p	A311V	0	.	.	931	933	GCA	1455	1457	GCA	115;115;114	G;C;A	98;99;102	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	752	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2786	80.7	1	SNP	p	I312M	0	.	.	934	936	ATC	1458	1460	ATC	115;115;115	A;T;C	102;101;100	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	752	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2786	80.7	1	SNP	p	V316P	0	.	.	946	948	GTG	1470	1472	GTG	112;112;115	G;T,C;G	100;98,1;100	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	752	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2786	80.7	1	SNP	p	V316T	0	.	.	946	948	GTG	1470	1472	GTG	112;112;115	G;T,C;G	100;98,1;100	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	752	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2786	80.7	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1974	1976	ACC	83;84;82	A;C,A;C,T,A	72;73,1;69,1,1	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	752	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2786	80.7	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2028	2030	GCG	78;78;77	G;C,G;G,T	65;59,1;63,1	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	752	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2786	80.7	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2028	2030	GCG	78;78;77	G;C,G;G,T	65;59,1;63,1	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	752	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2786	80.7	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2151	2153	GGC	71;71;72	G;G;C	63;64;62	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	752	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2786	80.7	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2160	2162	GGC	72;72;73	G;G;C	62;61;65	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	752	penA	1749	1749	100.0	penA.l6.c4.ctg.1	2786	80.7	1	SNP	p	P552S	0	.	.	1654	1656	CCG	2178	2180	CCG	76;77;79	C,G;C;G,A	67,1;68;64,1	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	1070	ponA	2397	2397	99.96	ponA.l15.c4.ctg.1	3488	91.8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	540	porA	1146	1146	99.83	porA.l6.c4.ctg.1	2405	67.3	0	.	p	.	0	M83fs	FSHIFT	247	247	A	874	874	C	104	C	87	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	594	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1762	98.7	0	.	p	.	0	E48G	NONSYN	142	144	GAA	625	627	GGA	129;130;130	G;G;A	102;111;112	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	594	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1762	98.7	0	.	p	.	0	G50N	NONSYN	148	150	GGC	631	633	AAC	130;130;131	A;A;C	114;112;112	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	594	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1762	98.7	0	.	p	.	0	F135L	NONSYN	403	405	TTT	886	888	CTT	119;118;118	C,A;T;T,C	100,1;101;97,1	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	594	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1762	98.7	0	.	p	.	0	R143G	NONSYN	427	429	AGA	910	912	GGA	108;109;109	G,A;G;A	93,1;91;90	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	594	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1762	98.7	0	.	p	.	0	D171G	NONSYN	511	513	GAT	994	996	GGT	114;114;115	G;G;T	95;94;96	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	594	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1762	98.7	0	.	p	.	0	G189S	NONSYN	565	567	GGC	1048	1050	AGC	127;128;129	A;G;C	111;112;113	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	594	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1762	98.7	0	.	p	.	0	Y211fs	FSHIFT	631	631	T	1114	1114	T	122	T	110	.	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	594	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1762	98.7	1	SNP	p	G120K	0	.	.	358	360	GGT	841	843	GGT	118;120;120	G;G;T	105;102;102	porB1b.WHO_U_02278c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	594	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1762	98.7	1	SNP	p	A121N	0	.	.	361	363	GCC	844	846	GCC	121;121;122	G;C,A;C	103;105,1;108	porB1b.WHO_U_02278c:1:1:A121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_U_02278c	porB1b.WHO_U_02278c	1	1	539	594	porB1b	1035	1035	95.63	porB1b.l15.c17.ctg.1	1762	98.7	1	SNP	p	A121D	0	.	.	361	363	GCC	844	846	GCC	121;121;122	G;C,A;C	103;105,1;108	porB1b.WHO_U_02278c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	1780	rpoB	4179	4179	100.0	rpoB.l6.c30.ctg.1	5476	97.1	1	SNP	p	H553N	1	.	.	1657	1659	AAT	2153	2155	AAT	93;93;94	A;A;T	81;80;77	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	272	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1232	65.5	1	SNP	p	V57M	1	.	.	169	171	ATG	589	591	ATG	115;116;117	A;T;G,T	97;99;97,1	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
